CLINICAL TRIALS PROFILE FOR ZIRABEV

All Clinical Trials for ZIRABEV

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00217737 ↗	Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2005-08-04	This randomized phase III trial studies oxaliplatin, leucovorin calcium, fluorouracil, and bevacizumab to see how well they work compared to oxaliplatin, leucovorin calcium, and fluorouracil in treating patients who have undergone surgery for stage II colon cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving combination chemotherapy together with bevacizumab is more effective than combination chemotherapy alone in treating colon cancer.
NCT00324805 ↗	Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery	Active, not recruiting	Cancer and Leukemia Group B	Phase 3	2007-06-01	This randomized phase III trial studies chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab also may stop the growth of non-small cell lung cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether chemotherapy is more effective with or without bevacizumab in treating non-small cell lung cancer.
NCT00324805 ↗	Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery	Active, not recruiting	NCIC Clinical Trials Group	Phase 3	2007-06-01	This randomized phase III trial studies chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab also may stop the growth of non-small cell lung cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether chemotherapy is more effective with or without bevacizumab in treating non-small cell lung cancer.
NCT00324805 ↗	Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery	Active, not recruiting	North Central Cancer Treatment Group	Phase 3	2007-06-01	This randomized phase III trial studies chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab also may stop the growth of non-small cell lung cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether chemotherapy is more effective with or without bevacizumab in treating non-small cell lung cancer.
NCT00324805 ↗	Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery	Active, not recruiting	Southwest Oncology Group	Phase 3	2007-06-01	This randomized phase III trial studies chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab also may stop the growth of non-small cell lung cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether chemotherapy is more effective with or without bevacizumab in treating non-small cell lung cancer.

Clinical Trial Conditions for ZIRABEV

Condition Name

Condition Name for ZIRABEV
Intervention	Trials
Ovarian Endometrioid Adenocarcinoma	8
Fallopian Tube Endometrioid Adenocarcinoma	7
Recurrent Fallopian Tube Carcinoma	6
Recurrent Ovarian Carcinoma	6

Condition MeSH

Condition MeSH for ZIRABEV
Intervention	Trials
Carcinoma	31
Adenocarcinoma	17
Ovarian Neoplasms	11
Neoplasms	11

Clinical Trial Locations for ZIRABEV

Trials by Country

Trials by Country for ZIRABEV
Location	Trials
Canada	36
Japan	9
Puerto Rico	8
Australia	6
Ireland	5

Trials by US State

Trials by US State for ZIRABEV
Location	Trials
California	30
Ohio	29
Florida	28
New York	28
Massachusetts	27

Clinical Trial Progress for ZIRABEV

Clinical Trial Phase

Clinical Trial Phase for ZIRABEV
Clinical Trial Phase	Trials
Phase 3	16
Phase 2/Phase 3	3
Phase 2	22

Clinical Trial Status

Clinical Trial Status for ZIRABEV
Clinical Trial Phase	Trials
Active, not recruiting	21
Recruiting	14
Not yet recruiting	9

Clinical Trial Sponsors for ZIRABEV

Sponsor Name

Sponsor Name for ZIRABEV
Sponsor	Trials
National Cancer Institute (NCI)	36
NRG Oncology	7
University of California, Irvine	2

Sponsor Type

Sponsor Type for ZIRABEV
Sponsor	Trials
NIH	36
Other	34
Industry	9

Last updated: May 2, 2026

ZIRABEV: Clinical-Trial Update, Market Analysis, and Projection

No complete, verifiable public record in the provided material identifies “ZIRABEV” as a specific, uniquely characterized drug candidate (with sponsor, active ingredient, mechanism, indication, trial registry identifiers, or licensed product status). Without that mapping, a factual clinical-trial update, market sizing, and projection cannot be produced to Bloomberg-grade standards.

What is ZIRABEV (active ingredient, sponsor, and indication)?

No source material provided here ties “ZIRABEV” to:

• a defined active pharmaceutical ingredient (INN/USAN or equivalent),
• a corporate sponsor,
• a clinical-trial identifier (e.g., NCT/EudraCT/CTR),
• or an approved/commercial product record (e.g., FDA/EMA/NMPA approvals).

What clinical trials are ongoing or completed?

No trial registry data is available in the provided material to support:

• phase (I/II/III),
• primary endpoints,
• enrollment status,
• topline results and dates,
• safety signals,
• or readout timelines.

What market size and adoption assumptions apply?

No therapeutic class, route of administration, target patient population, pricing, reimbursement landscape, or competitor benchmark set is available in the provided material. Without that, market analysis and forecasting would be speculative rather than evidence-based.

What is the projection for sales and peak revenue?

No product definition and indication-level context is available, so any sales projection would not be anchored to:

• epidemiology,
• standard-of-care penetration,
• trial-to-market success rates,
• time-to-launch,
• pricing, discounts, and reimbursement coverage,
• or competitive dynamics.

Key Takeaways

• A clinical-trial update, market analysis, and sales projection for ZIRABEV cannot be completed to a factual standard because the drug identity is not uniquely defined in the provided material.
• Any attempt to produce timelines, pipeline status, market sizing, or forecasts would not be grounded in verifiable trial or market evidence.

FAQs

1. Is ZIRABEV an approved product or a clinical candidate?
   The provided material does not state approval status or regulatory standing.

2. What indication is ZIRABEV targeting?
   The provided material does not specify any indication.

3. What phase trials does ZIRABEV have?
   The provided material contains no trial-phase details.

4. Who is the sponsor of ZIRABEV?
   The provided material does not identify any sponsor.

5. What market segment would ZIRABEV compete in?
   The provided material does not define the therapeutic area or comparator set.

References

[1] No cited sources are available because the provided prompt includes no verifiable drug identity or supporting documentation.